The nuclear receptor superfamily is a group of transcriptional regulators that control multiple aspects of both physiology and pathology, and are broadly recognized as viable therapeutic targets. While receptor-modulating drugs have been successful in many cases, the discovery of new drug targets is still an active area of research, because resistance to nuclear receptor-targeting therapies remains a significant clinical challenge. Many successful targeted therapies have harnessed the control of receptor activity by targeting events within the nuclear receptor signaling pathway. In this review, we explore the role of nuclear receptor ubiquitylation and discuss how the expanding roles of ubiquitin might be leveraged to identify additional entry points to control receptor function for future therapeutic development.